Synthesis and pharmacological evaluation of novel substituted and unsubstituted N-(benzoylphenyl)-1H-indole-2-carboxamides as potent antihypertriglyceridemic agents

Zeitschrift fur Naturforschung - Section C Journal of Biosciences

Volumn 65 C, Issue 5-6, 2010, Pages 309-316

  Shahwan, Moyad ^a   Shattat, Ghassan ^a   Al Qirim, Tariq ^a   Sheikha, Ghassan Abu ^a   Al Hiari, Yusuf ^b   El Huneidi, Waseem ^a   Jarab, Anan ^a   Al Najdawi, Manal ^b  

^a AL ZAYTOONAH UNIVERSITY OF JORDAN   (Jordan)

^b UNIVERSITY OF JORDAN   (Jordan)

Author keywords

(Benzoylphenyl) 1H indole 2 carboxamides; High density lipoprotein cholesterol level; Triglycerides reduction

Indexed keywords

EID: 77954971151     PISSN: 09395075     EISSN: None     Source Type: Journal    
DOI: 10.1515/znc-2010-5-601     Document Type: Article

References (24)

1. Al-Qirim T., Shahwan M., Shattat G., Al-Hiari Y., Abu Sheikha G., and Zaidi S. (2009), Pharmacological evaluation of novel indole-2-carboxamides as potent lipid-lowering agents in Triton-WR1339-induced hyperlipidemic rats. Z. Naturforsch. 64c, 619-625.
2. Anila L. and Vijayalakshmi N. R. (2002), Flavonoids from Emblica officinalis and Mangifera indica-effectiveness for dyslipidemia J. Ethnopharmacol. 79, 81-87.
3. Bosies E., Heerdt R., Kuknle H. F., Schmidt F. H., and Stach H. (1980), Hypoglycemically and hypolipidemically active derivatives of phenylalkane carboxylic acids. U.S. Patent 150207.
4. Braunwald S. E. (1997), Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N. Engl. J. Med. 337, 1360-1369.
5. Dasseux J. and Oniciu C. D. (2002), Aliphatic, aromatic, and heterocyclic ketone compounds and compositions for cholesterol management and related uses. U.S. Patent 325529.
6. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V., Mäenpää H., Mälkönen M., Mänttäri M., Norola S., Pasternack A., Pikkarainen J., Romo M., Sjöblom T., and Nikkilä E. A. (1987), Helsinki heart study: primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237-1245.
7. Frishman W. H. (1998), Biologic markers as predictors of cardiovascular disease. Am. J. Med. 104, 18S-27S.
8. Goldstein J. L., Hazzard W. R., Schrott H. G., Bierman E. L., and Motulsky A. G. (1973), Hyperlipidemia in coronary heart disease I. Lipid levels in 500 survivors of myocardial infarction. J. Clin. Invest. 52, 1533-1543.
9. Kalopissis A.-D., Griglio S., Malewiak M.-I., and Rosen R. (1980), Effect of a high-fat diet on rat very low density lipoprotein secretion. Biochim. Biophys. Acta 620, 111-119.
10. Khanna A. K., Rizvi F., and Chander R. (2002), Lipid lowering activity of Phyllanthus niruri in hyperlipemic rats. J. Ethnopharmacol. 82, 19-22.
11. Kopin A. S., Carey M., and Wang D. (2006), Altering intestinal motility and absorption of hydrophobic compounds through the use of agonists and/or antagonists of the cholecystokinin-1 receptor. U.S. Patent 224869.
12. Liu G., Zhang Z., Luo X., Shen J., Liu H., Shen X., Chen K., and Jiang H. (2004), Inhibitory mode of indole- 2-carboxamide derivatives against HLGPa: Molecular docking and 3D-QSAR analyses. Bioorg. Med. Chem. 15, 4147-4157.
13. Malloy M. J. and Kan J. P. (1994), Medical-management of hyperlipidemic states. Adv. Int. Med. 39, 603-631.
14. Olgen S. and Coban T. (2002), Synthesis and antioxidant properties of novel N-substituted indole-2-carboxamide and indole-3-acetamide derivatives. Arch. Pharm. 335, 331-338.
15. Otway S. and Robinson D. S. (1967), The effect of the nonionic detergent (Triton) on the removal of triglyceride fatty acids from the blood of the rats. J. Physiol. 190, 309-319.
16. Paoletti R. (1962), Comparative studies on hypocholesterolemic agents. Am. J. Clin. Nutr. 10, 277-284.
17. Raasch R. H. (1988), Hyperlipidemias in applied therapeutics. In: The Clinical Use of Drugs (Young L. Y. and Koda-Kimble M. A., eds.). Edwards Brothers, Ann Arbor, MI, pp. 1743-1745.
18. Robichaud L. J., Stewart S. F., and Adolphson R. L. (1987), CI-922-a novel, potent antiallergic compound. I. Inhibition of mediator release in vitro. Int. J. Immunopharmacol. 19, 41-49.
19. Rubins H. B., Robins S. J., Collins D., Fye C. L., Anderson J. W., Elam M. B., Faas F. H., Linares E., Schaefer E. J., Schectman G., Wilt T. J., and Wittes J. (1999), Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. N. Engl. J. Med. 341, 410-418.
20. Schoonjans K., Staels B., and Auwerx J. (1996), Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37, 907-925.
21. Schotz M. C., Scanu A., and Page I. H. (1957), Effect of Triton on lipoprotein lipase of rat plasma. Am. J. Physiol. 188, 399-402.
22. Schurr P. E., Schultz J. R., and Parkinson T. M. (1972), Triton induced hyperlipidaemia in rats as an animal model for screening hypolipidemic drugs. Lipids 7, 69-74.
23. Sher P. M. and Ellsworth B. A. (2004), Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds. U.S. Patent 140474.
24. Smith S. C., Jackson R., Pearson T. A., Fuster V., Yusuf S., Faergeman O., Wood D. A., Alderman M., Horgan J., Home P., Hunn M., and Grundy S. M. (2004), Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation 109, 3112-3121.